

Press release 3.15 p.m. EST, November 4, 2019

Bioprinting advanced skin architecture complete with blood vessels using CELLINK technology

A new study from Rensselaer Polytechnic Institute successfully demonstrates the use of CELLINK technology to produce living skin models.

In a new publication, a research team from Rensselaer Polytechnic Institute successfully bioprinted a living skin model complete with blood vessels using CELLINK's BIO X. Skin models like the one in the study are essential to developing natural skin grafts that enable accelerated wound healing and integration with host cells. The research team was led by Pankaj Karande, an associate professor of chemical and biological engineering and member of the Center for Biotechnology and Interdisciplinary Studies (CBIS), and the study was published in *Tissue Engineering Part* A on November 1.

According to Karande, the researchers used a "far more complex biology" approach to create a functioning vascular system. They combined human endothelial and pericyte cells with animal collagen and other structural cells common in skin grafts, bioprinted a complex skin structure and observed cell communication through the vascular structure formed.

This isn't the first time CELLINK's bioprinting technology has shown potential to solve challenges related to human health and skin. In May 2019, CELLINK announced a collaboration with Umeå University and GE Healthcare to develop bioprinted skin grafts to improve quality of life for burn patients.

For more information, please contact:

 Erik Gatenholm, CEO
 Gusten Danielsson, CFO

 Phone: EU +46 73 267 00 00
 Phone: +46 70 991 86 04

 US +1 (650) 515 5566
 US +1 (857) 332 2138

 Email: eg@cellink.com
 Email: gd@cellink.com

About CELLINK

CELLINK is the leading 3D bioprinter provider and the first bioink company in the world. We focus on developing and commercializing bioprinting technologies to allow researchers to print human organs and tissues for pharmaceutical and cosmetic applications. Founded in 2016 and active in more than 50 countries, CELLINK is changing the future of medicine as we know it. Visit www.cellink.com to learn more. CELLINK is listed on Nasdaq First North Growth Market under CLNK. Erik Penser Bank AB is the company's certified adviser, available by phone at +46 846 383 00 and by email at: certifiedadviser@penser.se.

